Tumor cell surface targets and potential therapies
| Category . | Target . | Potential agents . |
|---|---|---|
| Anti-CD20 mAbs, type I | CD20 | Rituximab |
| CD20 | Ofatumumab | |
| CD20 | Veltuzumab | |
| CD20 | Ocaratuzumab | |
| CD20 | Ublituximab | |
| Anti-CD20 mAbs, type II | CD20 | Obinutuzumb |
| Other mAbs | CD22 | Epratuzumab* |
| CD80 | Galiximab* | |
| CD37 | Otlertuzumab | |
| CD37 | BI 836826 | |
| HLA-DR | IMMU-114 | |
| Bispecific antibodies | CD3/CD19 | Blinatumumab |
| CD3/CD20 | BTCT4465A | |
| CD3/CD20 | REGN1979 | |
| CD3/CD19 | AFM11 | |
| ADCs | CD22 | Inotuzumab Ozogamycin |
| CD19 | Coltuximab Ravtansine | |
| CD79b | Polatuzumab Vedotin | |
| CD37 | IMGN529 | |
| CD37 | AGS67E | |
| CD19 | ADCT-402 | |
| CD25 | ADCT-301 | |
| CD19/CD22 | DT2219ARL |
| Category . | Target . | Potential agents . |
|---|---|---|
| Anti-CD20 mAbs, type I | CD20 | Rituximab |
| CD20 | Ofatumumab | |
| CD20 | Veltuzumab | |
| CD20 | Ocaratuzumab | |
| CD20 | Ublituximab | |
| Anti-CD20 mAbs, type II | CD20 | Obinutuzumb |
| Other mAbs | CD22 | Epratuzumab* |
| CD80 | Galiximab* | |
| CD37 | Otlertuzumab | |
| CD37 | BI 836826 | |
| HLA-DR | IMMU-114 | |
| Bispecific antibodies | CD3/CD19 | Blinatumumab |
| CD3/CD20 | BTCT4465A | |
| CD3/CD20 | REGN1979 | |
| CD3/CD19 | AFM11 | |
| ADCs | CD22 | Inotuzumab Ozogamycin |
| CD19 | Coltuximab Ravtansine | |
| CD79b | Polatuzumab Vedotin | |
| CD37 | IMGN529 | |
| CD37 | AGS67E | |
| CD19 | ADCT-402 | |
| CD25 | ADCT-301 | |
| CD19/CD22 | DT2219ARL |
ADCs, antibody-drug conjugates.
No longer in development in NHL.